Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.
Standardized criteria for diagnosis and response assessment are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Therefore, a National Cancer Institute-sponsored Working Group (NCI-WG) on chronic lymphocytic leukemia (CLL) published guidelines for the design and conduct of clinical trials for patients with CLL in 1988, which were updated in 1996. During the past decade, considerable progress has been achieved in defining new prognostic markers, diagnostic parameters, and treatment options. This prompted the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice.
Hallek
Michael
M
Klinik I für Innere Medizin, Universität zu Köln, Köln, Germany. michael.hallek@uni-koeln.de
Cheson
Bruce D
BD
Catovsky
Daniel
D
Caligaris-Cappio
Federico
F
Dighiero
Guillaume
G
Döhner
Hartmut
H
Hillmen
Peter
P
Keating
Michael J
MJ
Montserrat
Emili
E
Rai
Kanti R
KR
Kipps
Thomas J
TJ
D002986:Clinical Trials as Topic / Q000592:standards; D004493:Education; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis* / Q000628:therapy*; D054547:National Cancer Institute (U.S.) / Q000592:standards*; D014481:United States